Literature DB >> 18807007

The influence of a balanced volume replacement concept on inflammation, endothelial activation, and kidney integrity in elderly cardiac surgery patients.

Joachim Boldt1, Stephan Suttner, Christian Brosch, Andreas Lehmann, Kerstin Röhm, Andinet Mengistu.   

Abstract

PURPOSE: A balanced fluid replacement strategy appears to be promising for correcting hypovolemia. The benefits of a balanced fluid replacement regimen were studied in elderly cardiac surgery patients.
METHODS: In a randomized clinical trial, 50 patients aged >75 years undergoing cardiac surgery received a balanced 6% HES 130/0.42 plus a balanced crystalloid solution (n = 25) or a non-balanced HES in saline plus saline solution (n = 25) to keep pulmonary capillary wedge pressure/central venous pressure between 12-14 mmHg. Acid-base status, inflammation, endothelial activation (soluble intercellular adhesion molecule-1, kidney integrity (kidney-specific proteins glutathione transferase-alpha; neutrophil gelatinase-associated lipocalin) were studied after induction of anesthesia, 5 h after surgery, 1 and 2 days thereafter. Serum creatinine (sCr) was measured approximately 60 days after discharge.
RESULTS: A total of 2,750 +/- 640 mL of balanced and 2,820 +/- 550 mL of unbalanced HES were given until the second POD. Base excess (BE) was significantly reduced in the unbalanced (from +1.21 +/- 0.3 to -4.39 +/- 1.0 mmol L(-1) 5 h after surgery; P < 0.001) and remained unchanged in the balanced group (from 1.04 +/- 0.3 to -0.81 +/- 0.3 mmol L(-1) 5 h after surgery). Evolution of the BE was significantly different. Inflammatory response and endothelial activation were significantly less pronounced in the balanced than the unbalanced group. Concentrations of kidney-specific proteins after surgery indicated less alterations of kidney integrity in the balanced than in the unbalanced group.
CONCLUSIONS: A total balanced volume replacement strategy including a balanced HES and a balanced crystalloid solution resulted in moderate beneficial effects on acid-base status, inflammation, endothelial activation, and kidney integrity compared to a conventional unbalanced volume replacement regimen.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18807007     DOI: 10.1007/s00134-008-1287-1

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  30 in total

1.  Saline-induced hyperchloremic metabolic acidosis.

Authors:  John A Kellum
Journal:  Crit Care Med       Date:  2002-01       Impact factor: 7.598

2.  Hydroxyethyl starch: does our choice of colloid prevent or add to renal impairment?

Authors:  G H Mills
Journal:  Br J Anaesth       Date:  2007-02       Impact factor: 9.166

Review 3.  Biologic markers for the early detection of acute kidney injury.

Authors:  Won K Han; Joseph V Bonventre
Journal:  Curr Opin Crit Care       Date:  2004-12       Impact factor: 3.687

4.  Hydroxyethylstarch and osmotic-nephrosis-like lesions in kidney transplantation.

Authors:  C Legendre; E Thervet; B Page; A Percheron; L H Noël; H Kreis
Journal:  Lancet       Date:  1993-07-24       Impact factor: 79.321

5.  The effects of hydroxyethyl starches of varying molecular weights on platelet function.

Authors:  A Franz; P Bräunlich; T Gamsjäger; M Felfernig; B Gustorff; S A Kozek-Langenecker
Journal:  Anesth Analg       Date:  2001-06       Impact factor: 5.108

6.  Hextend, a physiologically balanced plasma expander for large volume use in major surgery: a randomized phase III clinical trial. Hextend Study Group.

Authors:  T J Gan; E Bennett-Guerrero; B Phillips-Bute; H Wakeling; D M Moskowitz; Y Olufolabi; S N Konstadt; C Bradford; P S Glass; S J Machin; M G Mythen
Journal:  Anesth Analg       Date:  1999-05       Impact factor: 5.108

7.  Half-molar sodium-lactate solution has a beneficial effect in patients after coronary artery bypass grafting.

Authors:  Xavier M Leverve; Cindy Boon; Tarmizi Hakim; Maizul Anwar; Erwin Siregar; Iqbal Mustafa
Journal:  Intensive Care Med       Date:  2008-06-18       Impact factor: 17.440

8.  Regulation of renal blood flow by plasma chloride.

Authors:  C S Wilcox
Journal:  J Clin Invest       Date:  1983-03       Impact factor: 14.808

Review 9.  Use of plasma volume expanders in myocardial revascularisation.

Authors:  J H Lacy; C B Wright
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

10.  Effect of chloride on renin and blood pressure responses to sodium chloride.

Authors:  T A Kotchen; R G Luke; C E Ott; J H Galla; S Whitescarver
Journal:  Ann Intern Med       Date:  1983-05       Impact factor: 25.391

View more
  16 in total

1.  Restricted intravenous fluid regimen reduces the rate of postoperative complications and alters immunological activity of elderly patients operated for abdominal cancer: a randomized prospective clinical trail.

Authors:  Tao Gao; Ning Li; Juan-juan Zhang; Feng-chan Xi; Qi-yi Chen; Wei-ming Zhu; Wen-kui Yu; Jie-shou Li
Journal:  World J Surg       Date:  2012-05       Impact factor: 3.352

Review 2.  The impact of fluid therapy on microcirculation and tissue oxygenation in hypovolemic patients: a review.

Authors:  Joachim Boldt; Can Ince
Journal:  Intensive Care Med       Date:  2010-05-26       Impact factor: 17.440

Review 3.  Ethical publishing in intensive care medicine: A narrative review.

Authors:  Christian J Wiedermann
Journal:  World J Crit Care Med       Date:  2016-08-04

Review 4.  Are renal adverse effects of hydroxyethyl starches merely a consequence of their incorrect use?

Authors:  Christiane S Hartog; Frank M Brunkhorst; Christoph Engel; Andreas Meier-Hellmann; Maximilian Ragaller; Tobias Welte; Evelyn Kuhnt; Konrad Reinhart
Journal:  Wien Klin Wochenschr       Date:  2011-03-01       Impact factor: 1.704

Review 5.  Perioperative administration of buffered versus non-buffered crystalloid intravenous fluid to improve outcomes following adult surgical procedures.

Authors:  Sohail Bampoe; Peter M Odor; Ahilanandan Dushianthan; Elliott Bennett-Guerrero; Suzie Cro; Tong J Gan; Michael Pw Grocott; Michael Fm James; Michael G Mythen; Catherine Mn O'Malley; Anthony M Roche; Kathy Rowan; Edward Burdett
Journal:  Cochrane Database Syst Rev       Date:  2017-09-21

6.  S3 guidelines for intensive care in cardiac surgery patients: hemodynamic monitoring and cardiocirculary system.

Authors:  M Carl; A Alms; J Braun; A Dongas; J Erb; A Goetz; M Goepfert; W Gogarten; J Grosse; A R Heller; M Heringlake; M Kastrup; A Kroener; S A Loer; G Marggraf; A Markewitz; D Reuter; D V Schmitt; U Schirmer; C Wiesenack; B Zwissler; C Spies
Journal:  Ger Med Sci       Date:  2010-06-15

7.  Update on transfusion solutions during surgery: review of hydroxyethyl starches 130/0.4.

Authors:  Ornella Piazza; Giuliana Scarpati; Rosalba Tufano
Journal:  Int J Gen Med       Date:  2010-10-05

Review 8.  Prevention of acute kidney injury and protection of renal function in the intensive care unit. Expert opinion of the Working Group for Nephrology, ESICM.

Authors:  Michael Joannidis; Wilfred Druml; Lui G Forni; A B Johan Groeneveld; Patrick Honore; Heleen M Oudemans-van Straaten; Claudio Ronco; Marie R C Schetz; Arend Jan Woittiez
Journal:  Intensive Care Med       Date:  2010-03       Impact factor: 17.440

9.  The impact of crystalloid and colloid infusion on the kidney in rodent sepsis.

Authors:  Martin Alexander Schick; Tobias Jobst Isbary; Nicolas Schlegel; Juergen Brugger; Jens Waschke; Ralf Muellenbach; Norbert Roewer; Christian Wunder
Journal:  Intensive Care Med       Date:  2009-11-05       Impact factor: 17.440

10.  Year in review in Intensive Care Medicine 2009: II. Neurology, cardiovascular, experimental, pharmacology and sedation, communication and teaching.

Authors:  Massimo Antonelli; Elie Azoulay; Marc Bonten; Jean Chastre; Giuseppe Citerio; Giorgio Conti; Daniel De Backer; François Lemaire; Herwig Gerlach; Goran Hedenstierna; Michael Joannidis; Duncan Macrae; Jordi Mancebo; Salvatore M Maggiore; Alexandre Mebazaa; Jean-Charles Preiser; Jerôme Pugin; Jan Wernerman; Haibo Zhang
Journal:  Intensive Care Med       Date:  2010-01-28       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.